Mean percentage changes (95% CI) in total testosterone, SHBG and free testosterone (mITT analysis). by Chanel Avenant (409756)

Subjects:

Pairwise comparisons of hormonal results for DMPA-IM vs NET-EN expressed as mean percentage differences (95% CI) (mITT analysis). by Chanel Avenant (409756)

Subjects:

Total testosterone (nmol/L), SHBG (nmol/L) and free testosterone (pmol/L) outcomes at baseline and 25 weeks (mITT analysis). by Chanel Avenant (409756)

Subjects:

Total testosterone (nmol/L), SHBG (nmol/L) and free testosterone (nmol/L), outcomes at baseline and 25 weeks (mITT analysis). by Chanel Avenant (409756)

Subjects:

Proliferation of intestinal crypt epithelial cells. by Matteo Dell’Anno (10724418)

Subjects:

Diet composition and nutritional values. by Taynara Aparecida Vieira (16401726)

Subjects:

Nutritional and metabolic analysis. by Taynara Aparecida Vieira (16401726)

Subjects:

Cardiovascular parameters. by Taynara Aparecida Vieira (16401726)

Subjects:

Mineral concentrations measured over time in blood plasma and intestinal lumen content. by Matteo Dell’Anno (10724418)

Subjects:

Cardiac inflammatory parameters. by Taynara Aparecida Vieira (16401726)

Subjects:

The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

“…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”

Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

“…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”

<i>Bbs1</i>^{<i>M390R/M390R</i>} mice have decreased hippocampal proliferation. by Thomas K. Pak (10686881)

“…At P30, mice were started on BrdU injections (2x50mg/kg) for five days. At P44, mice were taken down. …”

Salience of authority-virtue phrases by year. by Daniel Hart (440152)

Dose response of airways to Methacholine shows a decreased contractility in <i>GSTCD</i>^-/- mouse lungs following LPS treatment. by Bo Liu (127343)

Required soil organic carbon content and maximum strain energy density as a function of normalized water content for clay contents of 16% and 50%. by Siul Ruiz (757454)

FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD₅₀ = 8.4 μM, p ≤ 0.05). …”

DataSheet_1_Circulating exosomes decrease in size and increase in number between birth and age 7: relations to fetal growth and liver fat.pdf by Marta Díaz (337207)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”